Cannabidiol (CBD) Medicinal Products Reaching New Level of Acceptance in the Healthcare Industry

PALM BEACH, Florida, October 10, 2018 /PRNewswire/ --

Financialnewsmedia.com News Commentary 

The medicinal cannabis industry may appear to be lagging behind the legal niches of CBD and recreational cannabis, but the reality is, leaders in the space are still generating strong revenues behind increased momentum regarding how cannabis is viewed as a viable medical treatment. More researchers and medical professionals are interested in cannabis, and the need for education is pronounced. Efforts to educate patients are also gaining steam, especially as more people turn to medical marijuana for assistance in managing the symptoms of many different conditions. In order to capitalize on this momentum, companies are releasing new products with the hope of capturing new and emerging markets. The medicinal cannabis market has been steadily growing over the past few years and it is expected to grow to $55.8 billion by 2025, according to Grand View Research. Much of this growth will be due to momentum building on itself, but educational efforts, product advancements and a reduction in alcohol's popularity will also play roles in the growth. Active cannabis companies in the markets this week include Empower Clinics Inc. (CSE: EPW) (OTC: EPWCF), GW Pharmaceuticals plc. (NASDAQ: GWPH), MedMen Enterprises Inc. (OTC: MMNFF) (CSE: MMEN), Aphria Inc. (OTC: APHQF) (TSX: APH), Canopy Growth Corporation (NYSE: CGC) (TSX: WEED).

Empower Clinics Inc. (CSE: EPW) (OTCPK: EPWCF) BREAKING NEWS: Empower Clinics, a leading owner and operator of medical cannabis and wellness clinics in the US, today announced a comprehensive agreement with Titration Technologies, LLC, an innovator in cannabis product development, to manufacture, package, and fulfill Empower's 'Sollievo' CBD medical cannabis products throughout North America.

Empower's "Sollievo" (Italian for "relief") products specifically target the most common qualifying medical conditions, involving pain, sleep, stress, and digestion. The products, available as tinctures or topical creams, are non-THC CBD, meaning that they are non-psychotropic: they do not directly affect mood, perception, or consciousness.

As part of the agreement, Titration will produce Empower-formulated CBD medical cannabis products, which Empower will sell under its 'Sollievo' product brand on Empower's Website, at Empower clinics, as well as select third-party wellness clinics throughout the US and Canada. The products will be available at http://www.empowerclinics.com in the coming weeks.